KR950005866B1 - Edrf 효능 또는 그 생성을 차단하는 쇽 치료용 약제 - Google Patents

Edrf 효능 또는 그 생성을 차단하는 쇽 치료용 약제 Download PDF

Info

Publication number
KR950005866B1
KR950005866B1 KR1019900021355A KR900021355A KR950005866B1 KR 950005866 B1 KR950005866 B1 KR 950005866B1 KR 1019900021355 A KR1019900021355 A KR 1019900021355A KR 900021355 A KR900021355 A KR 900021355A KR 950005866 B1 KR950005866 B1 KR 950005866B1
Authority
KR
South Korea
Prior art keywords
edrf
compound
block
efficacy
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019900021355A
Other languages
English (en)
Korean (ko)
Other versions
KR910011253A (ko
Inventor
브라께 삐에르
샤브리에 드 라소니에르 삐에르-에띠엔느
귈롱 쟝-미쉘
오게뜨 미쉘
Original Assignee
소시에떼 드 꽁세이으 드 르셰르셰 에 다쁠리까시옹 시앙띠피끄(에스.세.에흐.아.에스.)
게라르 보푸르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소시에떼 드 꽁세이으 드 르셰르셰 에 다쁠리까시옹 시앙띠피끄(에스.세.에흐.아.에스.), 게라르 보푸르 filed Critical 소시에떼 드 꽁세이으 드 르셰르셰 에 다쁠리까시옹 시앙띠피끄(에스.세.에흐.아.에스.)
Publication of KR910011253A publication Critical patent/KR910011253A/ko
Application granted granted Critical
Publication of KR950005866B1 publication Critical patent/KR950005866B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1019900021355A 1989-12-22 1990-12-21 Edrf 효능 또는 그 생성을 차단하는 쇽 치료용 약제 Expired - Fee Related KR950005866B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898929076A GB8929076D0 (en) 1989-12-22 1989-12-22 Treatment of shock by blocking agents of edrf effect or formation
GB89-29076.1 1989-12-22
FR89290761 1989-12-22

Publications (2)

Publication Number Publication Date
KR910011253A KR910011253A (ko) 1991-08-07
KR950005866B1 true KR950005866B1 (ko) 1995-06-02

Family

ID=10668428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900021355A Expired - Fee Related KR950005866B1 (ko) 1989-12-22 1990-12-21 Edrf 효능 또는 그 생성을 차단하는 쇽 치료용 약제

Country Status (21)

Country Link
US (1) US5081148A (https=)
JP (1) JP2706578B2 (https=)
KR (1) KR950005866B1 (https=)
AT (1) AT403122B (https=)
AU (1) AU629777B2 (https=)
BE (1) BE1005531A5 (https=)
CA (1) CA2032904C (https=)
CH (1) CH681692A5 (https=)
DE (1) DE4041283C2 (https=)
DK (1) DK176168B1 (https=)
FR (1) FR2656220B1 (https=)
GB (2) GB8929076D0 (https=)
HK (1) HK134693A (https=)
IE (1) IE64403B1 (https=)
IT (1) IT1246511B (https=)
LU (1) LU87867A1 (https=)
MY (1) MY105328A (https=)
NL (1) NL194717C (https=)
OA (1) OA09337A (https=)
SE (1) SE504922C2 (https=)
ZA (1) ZA9010004B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE468881B (sv) * 1991-01-09 1993-04-05 Kabi Pharmacia Ab Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
US5385940A (en) * 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
US5585402A (en) * 1992-12-23 1996-12-17 Glaxo Wellcome Inc. Nitric oxide synthase inhibitors
US5436270A (en) * 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
GB9312204D0 (en) * 1993-06-14 1993-07-28 Zeneca Ltd Therapeutic composition
GB9312761D0 (en) * 1993-06-21 1993-08-04 Wellcome Found Amino acid derivatives
US6090846A (en) * 1994-06-01 2000-07-18 Glaxo Wellcome Inc. Substituted urea and isothiourea derivatives as no synthase inhibitors
US6297276B1 (en) 1993-10-04 2001-10-02 Glaxosmithkline Substituted urea and isothiourea derivatives as no synthase inhibitors
US6225305B1 (en) 1993-10-04 2001-05-01 Glaxo Wellcome Inc. Substituted urea and isothiorea derivatives as no synthase inhibitors
EP0724570B1 (en) 1993-10-21 1999-03-03 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
WO1995011014A1 (en) * 1993-10-21 1995-04-27 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
GB9404400D0 (en) * 1994-03-07 1994-04-20 Wood Pauline J Potentiation of bioreductive agents
ES2151055T3 (es) * 1994-03-10 2000-12-16 Searle & Co Derivados de l-n6-(1-iminoetil)lisina utiles como inhibidores de oxido nitrico sintasa.
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
FR2727111B1 (fr) * 1994-11-21 1997-01-17 Hoechst Lab Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
AU4467396A (en) * 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
EP2301562B1 (en) * 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
FR2730930B1 (fr) 1995-02-27 1997-04-04 Oreal Utilisation d'inhibiteurs de no-synthase pour diminuer l'effet irritant cutane de produits utilises dans le domaine cosmetique ou pharmaceutique
GB9504350D0 (en) * 1995-03-04 1995-04-26 Sod Conseils Rech Applic Arginine derivatives
WO1996033175A1 (en) * 1995-04-20 1996-10-24 G.D. Searle & Co. Cyclic amidino agents useful as nitric oxide synthase inhibitors
US5830917A (en) * 1995-09-11 1998-11-03 G. D. Searle & Co. L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
US5981511A (en) * 1996-03-06 1999-11-09 G.D. Searle & Co. Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US6620848B2 (en) 1997-01-13 2003-09-16 Smithkline Beecham Corporation Nitric oxide synthase inhibitors
US6369272B1 (en) 1997-01-13 2002-04-09 Glaxosmithkline Nitric oxide synthase inhibitors
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
AU4821799A (en) 1998-06-10 1999-12-30 G.D. Searle & Co. Heterobicyclic and tricyclic nitric oxide synthase inhibitors
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
WO2005063752A1 (en) 2003-12-30 2005-07-14 Vasopharm Biotech Gmbh 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931921A (en) * 1960-12-22 1963-07-24 Lab Roques Therapeutic compositions intended for the treatment of any hepatic malfunctionings
DE1767212B1 (de) * 1967-04-13 1971-05-06 Sumitomo Chemical Co Verfahren zur Herstellung injizierbarer Arzneimittel
FR2115060A1 (en) * 1970-11-26 1972-07-07 Metabio Freeze-dried acetylsalicylates of lysine and arginine - easily prepd derivs of aspirin
CA1029660A (en) * 1973-06-01 1978-04-18 Kyowa Hakko Kogyo Co. Prevention of gastric lesions
FR2320759A1 (fr) * 1975-08-11 1977-03-11 Union Pharma Scient Appl Solution d'acide acetylsalicylique extemporanee injectable
IT1127322B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici
IT1127321B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizione farmaceutiche aventi specifiche proprieta' terapeutiche nei confronti dell'edema polmonare acuto,di alcuni stati di shock e dell'iperfibrinolisi
JPS5781409A (en) * 1980-11-10 1982-05-21 Toko Yakuhin Kogyo Kk External plaster
JPS57197211A (en) * 1981-05-28 1982-12-03 Sumitomo Chem Co Ltd Useful eye drop composition
JPS57200361A (en) * 1981-06-03 1982-12-08 Sumitomo Chem Co Ltd "indomethacin(r)" pharmaceutical with low irritant action
JPH0236570B2 (ja) * 1985-05-30 1990-08-17 Toko Yakuhin Kogyo Kk Shoenchintsunankozai
JPS6239524A (ja) * 1985-08-13 1987-02-20 Toko Yakuhin Kogyo Kk 消炎鎮痛軟膏剤
IT1201511B (it) * 1985-12-23 1989-02-02 Italfarmaco Spa Derivati citoprotettivi in patologie a base ischemica,loro preparazione e composizioni che li cntengono
AU1489688A (en) * 1987-02-20 1988-09-14 Shriners Hospitals For Crippled Children Omega-3 fatty acids in traumatic injury treatment

Also Published As

Publication number Publication date
FR2656220A1 (fr) 1991-06-28
FR2656220B1 (fr) 1995-01-13
IT9022413A0 (it) 1990-12-18
AU6837690A (en) 1991-06-27
GB2240041A (en) 1991-07-24
NL9002720A (nl) 1991-07-16
AU629777B2 (en) 1992-10-08
JPH04364124A (ja) 1992-12-16
GB8929076D0 (en) 1990-02-28
GB9028013D0 (en) 1991-02-13
SE504922C2 (sv) 1997-05-26
ZA9010004B (en) 1991-10-30
IT1246511B (it) 1994-11-19
KR910011253A (ko) 1991-08-07
LU87867A1 (fr) 1991-05-07
GB2240041B (en) 1993-09-01
IT9022413A1 (it) 1991-06-23
JP2706578B2 (ja) 1998-01-28
ATA260690A (de) 1997-04-15
SE9003974L (sv) 1991-06-23
CA2032904A1 (en) 1991-06-23
NL194717C (nl) 2003-01-07
SE9003974D0 (sv) 1990-12-12
DK176168B1 (da) 2006-11-13
AT403122B (de) 1997-11-25
NL194717B (nl) 2002-09-02
IE904592A1 (en) 1991-07-03
DE4041283C2 (de) 2000-07-13
MY105328A (en) 1994-09-30
CA2032904C (en) 1996-01-02
IE64403B1 (en) 1995-08-09
DE4041283A1 (de) 1991-06-27
OA09337A (fr) 1992-09-15
CH681692A5 (https=) 1993-05-14
BE1005531A5 (fr) 1993-09-28
HK134693A (en) 1993-12-17
US5081148A (en) 1992-01-14
DK304190A (da) 1991-06-23
DK304190D0 (da) 1990-12-21

Similar Documents

Publication Publication Date Title
KR950005866B1 (ko) Edrf 효능 또는 그 생성을 차단하는 쇽 치료용 약제
el Nasr et al. Neuroprotective effect of memantine demonstrated in vivo and in vitro
DE69031033T2 (de) Verwendung von eicosapentaensäure zur behandlung der kachexie
CA2147123C (en) Use of a cell membrane permeant calcium buffer for reducing injury of mammalian cells in vivo
KR20080047398A (ko) 아세틸시스테인 조성물 및 그의 용도
KR100720970B1 (ko) 진세노사이드 Ｒｂ₁을 함유하는 뇌세포 또는 신경세포보호제
KR100516827B1 (ko) 일산화질소생산억제제
US5990153A (en) Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury
Gratwohl et al. Cyclosporine toxicity in rabbits
EP0679080B1 (de) L-arginin und analoge als thrombozytenaggregationshemmer
GB2269748A (en) Composition for treatment of sickle cell disease
IL146032A (en) Use of N-acetylcysteine for the preparation of appropriate intravenous drugs to prevent oxidative stress in dialysis patients
DE60313627T2 (de) Kardioprotektive therapien auf basis von enzymatischer eliminierung von lipidperoxiden durch allenoxid-synthase
Kross et al. No dantrolene protection in a dog model of complete cerebral ischaemia
Shatat et al. Liver protection from acetaminophen hepatotoxicity using copper (I)-nicotinic acid complex
McCully et al. Antineoplastic activity of N-maleamide homocysteine thiolactone amide encapsulated within liposomes
Parker et al. Verapamil attenuates lung vascular responses to endotoxin in sheep
WO1999004783A1 (en) Composition for protection from damage by ischemia
CN102526035A (zh) 一种用于制备抗脑血管疾病药物的组合物
JPH04164029A (ja) 活性酸素障害防御剤
Anderson et al. Acute Toxicity of Trypan Blue, Gentian Violet and Brilliant Green.
US20210161993A1 (en) Method for accelerated healing of burn wounds
CN112438970A (zh) 米那普仑或/和米那普仑的药用盐的新用途
CN112603917A (zh) 辣椒素酯的新用途
Iyamu et al. Drug therapy for sickle cell disease

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19980603

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19980603

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000